Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio (HDST) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2022: -0.009x
Based on the latest financial reports, Hadasit Bio (HDST) has a cash flow conversion efficiency ratio of -0.009x as of June 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-360.50K) by net assets (ILA39.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hadasit Bio - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Hadasit Bio's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hadasit Bio Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hadasit Bio ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LHC
VN:LHC
|
N/A |
|
COMPUTER MODELLING
BE:5TJ
|
-0.034x |
|
Biome Grow Inc
PINK:BIOIF
|
0.000x |
|
Sonovia Ltd
TA:SONO
|
-0.245x |
|
C3is Inc.
NASDAQ:CISS
|
0.031x |
|
KORIAN (KO2.SG)
STU:KO2
|
N/A |
|
TAMINCO
F:T4M
|
N/A |
|
ViroMed Co Ltd
KO:084990
|
N/A |
Annual Cash Flow Conversion Efficiency for Hadasit Bio (2013–2022)
The table below shows the annual cash flow conversion efficiency of Hadasit Bio from 2013 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | ILA35.08 Million | ILA-2.12 Million | -0.060x | -88.52% |
| 2021-12-31 | ILA65.69 Million | ILA-2.10 Million | -0.032x | +70.05% |
| 2020-12-31 | ILA37.11 Million | ILA-3.96 Million | -0.107x | +81.53% |
| 2019-12-31 | ILA5.50 Million | ILA-3.18 Million | -0.578x | -20.50% |
| 2018-12-31 | ILA34.30 Million | ILA-16.46 Million | -0.480x | -65.93% |
| 2017-12-31 | ILA60.79 Million | ILA-17.57 Million | -0.289x | -21.36% |
| 2016-12-31 | ILA61.62 Million | ILA-14.68 Million | -0.238x | -8.35% |
| 2015-12-31 | ILA60.30 Million | ILA-13.26 Million | -0.220x | +60.29% |
| 2014-12-31 | ILA22.11 Million | ILA-12.24 Million | -0.554x | -18.68% |
| 2013-12-31 | ILA24.89 Million | ILA-11.61 Million | -0.467x | -- |